GeoVax Labs (GOVX) Interest Expenses (2011 - 2026)

GeoVax Labs (GOVX) posted quarterly Interest Expenses of $338167.0 for Q2 2026, up 19.83% quarter-over-quarter from $282211.0 in Q3 2025.

GeoVax Labs (GOVX) Interest Expenses (2011 - 2026) Analysis & Trends

GeoVax Labs (GOVX) has reported Interest Expenses for 14 consecutive years, with $338167.0 the latest figure, recorded in Q2 2026.

In Q2 2026, Interest Expenses changed N/A year-over-year to $338167.0; the TTM figure through Jun 2026 stood at $338167.0 (up 1482.07% YoY), while the FY2025 annual figure was $42.9 million, up 16.63% from the prior year.
Interest Expenses improved to $338167.0 in Q2 2026 per GOVX's latest filing, from $282211.0 in the prior quarter.
Across five years, Interest Expenses topped out at $338167.0 in Q2 2026 and bottomed at $7292.0 in Q2 2024.
Historically, Interest Expenses has averaged $160438.2 across 3 years, with a median of $148147.0 in 2024.
On a YoY basis, Interest Expenses climbed as much as 1903.91% in 2025 and fell as far as 1903.91% in 2025.
GeoVax Labs' Interest Expenses stood at $14083.0 in 2024, then jumped by 1903.91% to $282211.0 in 2025, then rose by 19.83% to $338167.0 in 2026.
Business Quant data shows GOVX's Interest Expenses at $338167.0 in Q2 2026, $282211.0 in Q3 2025, and $14083.0 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Expense (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	11.00 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	39.74 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	82.05 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-4.89 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	20.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	93.62 Mn
10	GeoVax Labs	2.88 Mn	-260,493.75	-	-

Download Data